PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness and safety of its drug PGN-EDO51, leading to significant stock price declines and investor losses [2][4]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, to discuss their legal options [1]. - The firm reminds investors of the August 11, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against PepGen [2]. - The complaint alleges that PepGen and its executives made false and misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study, which was deemed deficient for FDA approval [4]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a stock price drop of $5.55 per share, or 32.69%, closing at $11.43 [5][6]. - Following a clinical hold notice from the FDA on December 16, 2024, regarding the CONNECT2 study, PepGen's stock fell by $0.17 per share, or 3.63%, to close at $4.51 [7][8]. - On January 29, 2025, PepGen disclosed safety concerns in the CONNECT1 study, resulting in a stock price decline of $0.40 per share, or 21.74%, closing at $1.44 [9][10]. - The company announced a voluntary pause of the CONNECT2 study on March 4, 2025, leading to a further stock drop of $0.53 per share, or 18.86%, closing at $2.28 [10]. - On May 28, 2025, PepGen disclosed that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].